PRS was composed of a tumor matrix targeting peptide of palmitic-K(palmitic)CREKA, Rapamycin (mTOR inhibitor), and SBC-115076 (PCSK9 inhibitor), which could self-assemble into a uniform nanomedicine with good stability (Scheme 1A). Here, MTOR is linked to neoplasm.